Clarapath, a medical robotics company automating the laboratory has secured $36 Million B-1 Funding led by Northwell Ventures with additional new strategic investors including CU Healthcare Innovation Fund, Mayo Clinic, and Ochsner Ventures, bringing the company’s total funding to $75 million.
Read also – [Funding News] Star Catcher Secures $12.25 Million Seed Funding
With this new capital, Clarapath will further accelerate the commercialization of SectionStar. The funds will also be used to expand sales and service, precision manufacturing capabilities, and continue the company’s robust R&D pipeline.
Read also – [Funding News] Lakera Raises $20 Million Series A Funding
“Our strategic investors share in our mission to significantly overhaul this critical aspect of patient care that has long been overlooked,” said Eric Feinstein, CEO of Clarapath. “As labs adopt digital pathology downstream, automation in prior steps is crucial to establish consistent results and provide best-in-class samples for diagnostic review. Our automation and new digital tools capture and aggregate never-before-seen data, ultimately benefiting patients with faster results and less subjectivity.”
“Innovation is embedded in Northwell’s culture and integral to the way we approach investment in novel solutions which improve patient care and lower cost.” said Rich Mulry, CEO of Northwell Holdings. “We identified Clarapath seven years ago as a company with a bold vision to radically change laboratory medicine and are committed to continued support of their progressive journey which will transform medical diagnostics.”
About Clarapath
Clarapath is a medical robotics company automating the laboratory. Clarapath first product is focused on automating the microtomy station in pathology. Clarapath vision is to innovate, standardize, and digitally transform anatomic pathology through higher quality lab medicine, more robust safety standards, increased lab throughput, while lowering laboratory costs and labor related delays.
